SAN DIEGO, July 28, 2016 /PRNewswire/ -- Sequenom, Inc.,
(NASDAQ: SQNM), a life sciences company committed to enabling
healthier lives through the development of innovative products and
services, announced on July 27, 2016
that it entered into a definitive agreement and plan of merger with
Laboratory Corporation of America® Holdings
(LabCorp®) under which LabCorp would acquire all of the
outstanding shares of Seqeunom in a cash tender offer. In light of
this announcement, Sequenom has cancelled its second quarter
2016 earnings conference call scheduled to take place on
Wednesday, August 3, 2016 at
5:00 p.m. ET (2:00 p.m. PT).
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier
lives through the development of innovative products and services.
The Company serves patients and physicians by providing early
patient management information. To learn how Sequenom is
interpreting the genome to improve your life, please visit
www.sequenom.com.
About Sequenom Laboratories
Sequenom Laboratories, a CAP-accredited and CLIA-certified
molecular diagnostics laboratory, has developed a broad range of
laboratory tests, with a focus principally on prenatal care.
Branded under the names HerediT®, MaterniT®,
NextView®, SensiGene® and VisibiliT™, these
molecular genetic laboratory-developed tests provide early patient
management information for obstetricians, geneticists, and maternal
fetal medicine specialists. Sequenom Laboratories is changing the
landscape in genetic diagnostics using proprietary cutting edge
technologies. Please visit www.sequenom.com.
SEQUENOM®, HerediT®, MaterniT®,
NextView®, SensiGene®, VisibiliT™ and
Sequenom Laboratories™ are trademarks of Sequenom, Inc. All other
trademarks and service marks are the property of their respective
owners.
Logo -
http://photos.prnewswire.com/prnh/20160225/337675LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sequenom-announces-cancellation-of-second-quarter-2016-results-conference-call-300305296.html
SOURCE Sequenom, Inc.